VEGFR/PDGFR-IN-2


CAS No. : 919279-04-2

919279-04-2
Price and Availability of CAS No. : 919279-04-2
Size Price Stock
100 mg Get quote
250 mg Get quote
500 mg Get quote
We match the lowest price on market.

We offer a substantial discount on larger orders, please inquire via [email protected]

or Fax: (86)21-58955996

Inquiry for price and availability only. Please place your order via our email or fax.

Cat. No. : HY-18180
M.Wt: 445.38
Formula: C21H15F4N5O2
Purity: >98 %
Solubility:
Introduction of 919279-04-2 :

VEGFR/PDGFR-IN-2 is a VEGFR1/2/3, PDGFRα/β, and Tie-2 tyrosine kinase inhibitor. VEGFR/PDGFR-IN-2 inhibits endothelial tube formation and endothelial migration by blocking VEGF-induced receptor phosphorylation and PDGF-BB signaling, reduces tumor microvessel density, pericyte recruitment, and tumor interstitial fluid pressure, and enhances the antitumor activity of CPT-11. VEGFR/PDGFR-IN-2 can be used for research on solid tumors[1]. In Vitro:VEGFR/PDGFR-IN-2 (compound 20d) (3 days) inhibited the proliferation of cultured cancer cell lines with IC50 values of 3.5-7.2 µM[1].
VEGFR/PDGFR-IN-2 inhibits VEGFR1, VEGFR2, VEGFR3, PDGFRα, PDGFRβ, and Tie-2 kinase activity with IC50 values of 15, 6.2, 10, 35, 96, and 20 nM, respectively[1].
VEGFR/PDGFR-IN-2 (0.064-200 nM; 2 h) inhibits VEGF-induced VEGFR2 phosphorylation in HUVECs and PDGF-BB-induced PDGFRβ phosphorylation in CASMCs, with IC50 values of 2.5 and 3.6 nM, respectively[1].
VEGFR/PDGFR-IN-2 (5 days) inhibits VEGF-stimulated HUVEC proliferation with an IC50 of 2.8 nM[1].
VEGFR/PDGFR-IN-2 (6 days) inhibits PDGF-BB-stimulated CASMC proliferation with an IC50 of 9.6 nM[1].
VEGFR/PDGFR-IN-2 (0.3-10 nM; 7 days) inhibits VEGF-induced tube formation in HUVECs co-cultured with normal human dermal fibroblasts, with an IC50 of 3.3 nM[1]. In Vivo:VEGFR/PDGFR-IN-2 (compound 20d) (1.5-10 mg/kg; oral; twice daily or once daily; 3-21 days) produced dose-dependent antitumor activity in A549 xenograft mice and reduced tumor microvessel density and perivascular pericyte recruitment[1].
VEGFR/PDGFR-IN-2 (1.5-5.0 mg/kg; oral; twice daily; days 2-21) inhibits HT-29 tumor growth and reduces tumor interstitial fluid pressure, enhancing intratumoral uptake of CPT-11 and its active metabolite SN-38[1].

Your information is safe with us.